The Johnson & Johnson brand is displayed at firm places of work on October 17, 2023 in Irvine, California.
Mario Tama | Getty Photographs
Johnson & Johnson, recent off a $14.6 billion deal to purchase neurological drugmaker Intra-Cellular, reported fourth-quarter gross sales and revenue above Wall Avenue estimates on Wednesday, pushed by robust gross sales of its most cancers remedies.
The New Jersey-based drugmaker additionally stated it expects 2025 gross sales of between $90.9 billion and $91.7 billion and earnings between $10.75 and $10.95 per share on an adjusted foundation. Analysts had been anticipating gross sales of $90.98 billion and a revenue of $10.56 per share for 2025, in accordance with knowledge compiled by LSEG.
J&J’s fourth-quarter gross sales stood at $22.52 billion, up 5.3% from a yr in the past and above analysts’ expectations of $22.42 billion, in accordance with LSEG knowledge.
On an adjusted foundation, the corporate earned $2.04 per share within the quarter – which features a 22 cents cost associated to its acquisition of medical gadget maker V-Wave – almost 11% decrease than the earlier yr however beating analysts’ estimates of $2.01 per share.
Quarterly gross sales of J&J’s most cancers medication rose 19% worldwide, pushed by greater than $3 billion for a number of myeloma remedy Darzalex, which was up 20.9% from a yr in the past.
“Darzalex continues to be a pillar model with respect to efficiency,” stated J&J Chief Monetary Officer Joe Wolk in an interview, noting that gross sales from Shockwave Medical additionally helped drive progress.
The corporate is fostering progress at its medical gadget unit by way of offers targeted on coronary heart well being – together with its $13.1 billion deal to accumulate Shockwave Medical.
Shockwave generated $258 million in gross sales for the quarter and $564 million for the yr, in accordance with J&J.
J&J’s revolutionary medication unit introduced in fourth-quarter gross sales of $14.33 billion whereas its medtech unit generated $8.19 billion, up 4.4% and 6.7% respectively in comparison with a yr in the past.
Gross sales of J&J’s blockbuster psoriasis remedy Stelara fell 14.7% to $2.35 billion within the fourth quarter. Analysts’ had been anticipating gross sales of $2.25 billion, in accordance with LSEG knowledge.
Shut copies of Stelara launched in Europe, Canada and some different markets final yr. A number of Stelara biosimilars are anticipated to launch within the U.S. this yr.
For the total yr, Stelara introduced in income of $10.36 billion, making up greater than 18% of J&J’s whole drug gross sales of $56.96 billion for 2024. Analysts had been anticipating gross sales of $10.59 billion.
Annual gross sales of the drug are anticipated to fall to about $7 billion this yr.
Darzalex introduced in annual gross sales of $11.67 billion, making it J&J’s biggest-selling drug. Analysts had been anticipating gross sales of $11.11 billion for this yr.
Source link